BioLineRx (BLRX) Total Current Liabilities (2011 - 2025)

BioLineRx's Total Current Liabilities history runs 15 years deep, the most recent figure standing at $12.1 million for Q4 2025.

• On a quarterly basis, Total Current Liabilities fell 21.31% year-over-year to $12.1 million in Q4 2025; TTM through Dec 2025 was $12.1 million, a 21.31% decrease from a year earlier, with the FY2025 full-year figure at $12.1 million, down 21.31% from the prior year.
• Total Current Liabilities slipped to $12.1 million in Q4 2025 per BLRX's latest filing, from $13.7 million in the prior quarter.
• Across five years, Total Current Liabilities topped out at $42.8 million in Q4 2023 and bottomed at $8.1 million in Q3 2022.
• The 5-year median for Total Current Liabilities is $12.3 million (2023), against an average of $15.9 million.
• Across the five-year window, Total Current Liabilities soared 300.64% in 2023 and tumbled 63.99% in 2024, its largest moves.
• Year by year, Total Current Liabilities stood at $9.7 million in 2021, then gained by 9.88% to $10.7 million in 2022, then surged by 300.64% to $42.8 million in 2023, then tumbled by 63.99% to $15.4 million in 2024, then decreased by 21.31% to $12.1 million in 2025.
• Per Business Quant, the three latest BLRX Total Current Liabilities figures stand at $12.1 million (Q4 2025), $13.7 million (Q3 2025), and $15.5 million (Q2 2025).